Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to ...

Investors were surely discovering drug discovery company AbCellera Biologics (NASDAQ: ABCL) as the trading week kicked off on ...

Alexandria is a contrarian Buy opportunity with a 7.5% yield, robust fundamentals, & growth potential. See why ARE is Ideal ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion." ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

The transaction involves the sale of 2.44 crore shares at a floor price of ₹580 apiece, representing a discount of around 6.4 ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today ...

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Zydus Lifesciences acquires 5.9% stake in Agenus Inc for $16 million, marking entry into the global biologics contract ...